{"id":17329,"date":"2024-03-27T12:46:48","date_gmt":"2024-03-27T12:46:48","guid":{"rendered":"https:\/\/shareperformanceinsight.com\/index.php\/2024\/03\/27\/pro-life-groups-assail-fda-for-reckless-disregard-in-supreme-court-abortion-pill-case\/"},"modified":"2024-03-27T12:46:48","modified_gmt":"2024-03-27T12:46:48","slug":"pro-life-groups-assail-fda-for-reckless-disregard-in-supreme-court-abortion-pill-case","status":"publish","type":"post","link":"https:\/\/shareperformanceinsight.com\/index.php\/2024\/03\/27\/pro-life-groups-assail-fda-for-reckless-disregard-in-supreme-court-abortion-pill-case\/","title":{"rendered":"Pro-life groups assail FDA for \u2018reckless disregard\u2019 in Supreme Court abortion pill case"},"content":{"rendered":"
\n

Pro-life leaders are accusing the Food and Drug Administration (FDA) of operating with a \u2018reckless disregard for women\u2019s health and safety\u2019 over the agency\u2019s handling of a controversial abortion pill that\u2019s now at the center of a high-stakes high court case.<\/p>\n

The U.S. Supreme Court on Tuesday heard arguments in a case that could curb nationwide access to abortion pills such as mifepristone \u2014 the drug that\u2019s drawn the ire of the pro-life community, including March for Life President Jeanne Mancini.\u00a0<\/p>\n

\u2018The FDA\u2019s removal of nearly all safeguards around the dangerous abortion drug mifepristone has needlessly put women and girls at risk for suffering severe \u2014 even life-threatening \u2014 complications without the ongoing care of a medical provider,\u2019 Mancini said. \u2018We hope the FDA will be held accountable for failing to meet its own standards when it comes to abortion drugs. Such reckless disregard for women\u2019s health and safety is unacceptable from an agency tasked with protecting it.\u2019<\/p>\n

The case, FDA v. Alliance for Hippocratic Medicine, centers around mifepristone. Approved by the FDA in 2000, the medication is used alongside another drug to end a pregnancy as early as 10 weeks gestation.<\/p>\n

The FDA took strides in 2021 \u2014 the year before the Supreme Court\u2019s June 2022 ruling that overturned Roe v. Wade \u2014 to make mifepristone more accessible, including by removing the requirement for patients to see a doctor in person to get a prescription.\u00a0<\/p>\n

But months after the Supreme Court\u2019s landmark summer decision, a federal appeals court in Texas ruled the FDA\u2019s policy change was illegal, as was an earlier update that extended the pill\u2019s recommended usage by several weeks. The high court is now reviewing that decision.<\/p>\n

\u2018Bowing to pressure from the abortion industry, the FDA loosened the safety requirements of mifepristone which still has a black box warning,\u2019 National Right to Life President Carol Tobias said. \u2018Drugs that come with black box warnings have the most dangerous side effects and safety concerns, yet the FDA is okay with mifepristone being prescribed and even mailed to women without an in-person exam.\u2019<\/p>\n

SBA Pro-Life America President Marjorie Dannenfelser told Fox News Digital that she \u2018was proud to stand with women harmed by abortion drugs courageously sharing their stories, and with the doctors caring for them, in contrast to the abortion industry that leaves women to suffer alone.\u2019<\/p>\n

\u2018Today we are standing up to say women\u2019s health matters and the FDA must do its job. We urge the Supreme Court to uphold safeguards for women and girls,\u2019 she said.<\/p>\n

Erik Baptist, senior counsel of Alliance Defending Freedom, said that pro-life groups\u00a0are \u2018simply asking the Court to reinstate the original standards that were in effect for over 15 years.\u2019<\/p>\n

Meanwhile, pro-choice groups are maintaining that mifepristone is a safe and critical drug in the post-Roe landscape of reproductive health.<\/p>\n

\u2018Decades of research and clinical experience have demonstrated that mifepristone is extraordinarily safe and effective, including when dispensed by pharmacies or through the mail,\u2019 Rabia Muqaddam, senior staff attorney at the Center for Reproductive Rights, told Fox News Digital. \u2018There is no legitimate science disputing this research. Instead, the plaintiffs in the case rely on widely discredited and even retracted research articles and the say-so of anti-abortion zealots.\u2019<\/p>\n

Muqaddam added: \u2018If the Supreme Court sides with the plaintiffs and their junk science over the FDA and decades of high-quality research, countless people will suffer as will the ability of Americans to access important drug innovations.\u2019<\/p>\n

Planned Parenthood President Alexis McGill Johnson cast the case as a \u2018threat\u2019 to women\u2019s rights \u2014 and more.<\/p>\n

\u2018Beyond the threat to our fundamental rights, the very existence of this case puts every other FDA-approved medication at risk of being taken off the market or restricted for political reasons,\u2019 Johnson said. \u2018That is reason enough to be clear about how serious this case is for the future of sexual and reproductive health care and everything beyond.\u2019<\/p>\n<\/div>\n

This post appeared first on FOX NEWS<\/div>","protected":false},"excerpt":{"rendered":"

Pro-life leaders are accusing the Food and Drug Administration (FDA) of operating with a \u2018reckless disregard for women\u2019s health and safety\u2019 over the agency\u2019s handling of a controversial abortion pill that\u2019s now at the center of a high-stakes high court case. The U.S. Supreme Court on Tuesday heard arguments in a case that could curb <\/p>\n","protected":false},"author":0,"featured_media":17330,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":{"0":"post-17329","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-politics"},"_links":{"self":[{"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/posts\/17329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/comments?post=17329"}],"version-history":[{"count":0,"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/posts\/17329\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/media\/17330"}],"wp:attachment":[{"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/media?parent=17329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/categories?post=17329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/shareperformanceinsight.com\/index.php\/wp-json\/wp\/v2\/tags?post=17329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}